A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen.
Six professional organizations including the Society for Pediatric Radiology made their case in a joint statement published across multiple medical journals Nov. 25.
“Becoming an independent department elevates this work and strengthens UCLA’s role in shaping the future of precision health," said the department's new acting chairman.
Although uncommon and typically not life-threatening, hypersensitivity reactions have increased in recent decades alongside the significant rise in CT use.
One of the tracer’s more significant advantages is its extended half-life of 109 minutes—significantly longer than other currently available PET MPI imaging agents.
Last month, the insurance giant announced it will begin charging hospitals a 10% administrative penalty for claims that involve docs outside of its networks.
The country’s largest imaging group is buying Palo Alto, California-based Cognita Imaging Inc., which was founded by scientists at Stanford University.
Six years ago, two radiologists with dissimilar backgrounds and divergent clinical interests put their heads together and launched a new practice. One physician was an academic subspecialized in musculoskeletal reads. The other, a private practitioner, concentrated on oncologic imaging. That’s how Transparent Imaging was born, powered by Konica Minolta.
In a private dining room in Miami, something unusual is happening. Leaders from competing imaging centers are openly discussing their best practices—even sharing vendor recommendations and operational strategies that have doubled their volumes while cutting costs in half.
A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen.
Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.
